Tuberculosis chemotherapy in the 21st century: Back to the basics

Lung India

Volumn 28, Issue 3, 2011, Pages 193-200

  Joshi, Jyotsna M ^a  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

Author keywords

extensive drug (XDR) resistant; Extremely drug resistant (XXDR) TB; first line drugs; multidrug resistant (MDR) TB; second line drugs; total drug resistant (TDR) TB

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; DIGITOXIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; KETOCONAZOLE; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PNU 100480; PREDNISOLONE; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; SALICYLIC ACID; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ACNE; ACUTE KIDNEY FAILURE; ANEMIA; ANOREXIA; ANTIMICROBIAL ACTIVITY; ANXIETY; ARTHRALGIA; ATAXIA; COGNITIVE DEFECT; COMA; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EXFOLIATIVE DERMATITIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEADACHE; HEARING LOSS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPERURICEMIA; HYPOTHYROIDISM; INSOMNIA; KIDNEY FAILURE; LIVER DISEASE; METABOLIC ACIDOSIS; MINIMUM INHIBITORY CONCENTRATION; MOOD CHANGE; MOOD DISORDER; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEURITIS; NEUROMUSCULAR BLOCKING; NONHUMAN; NYSTAGMUS; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PREGNANCY; PROTEINURIA; PSYCHOSIS; REVIEW; SEIZURE; SHORT COURSE THERAPY; SHOULDER HAND SYNDROME; SIDE EFFECT; THERAPY RESISTANCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; TUBERCULOSIS CONTROL; UNCONSCIOUSNESS; URTICARIA;

EID: 80052552503     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.83977     Document Type: Review

References (67)

1. Reichman LB. Tuberculosis elimination-what's to stop us? Int J Tuberc Lung Dis 1997;1:3-11.
2. Toman K. Tuberculosis case finding and chemotherapy: Questions and answers. Geneva: WHO; 1979.
3. Girling DJ, Coolet P. Anti-tuberculosis regimens of chemotherapy. Recommendations from the committee on treatment of International union against tuberculosis and lung disease. Indian J Chest Dis Allied Sci 1988;30:296-304.
4. American thoracic society diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990;192:725-35.
5. Joint tuberculosis committee chemotherapy and management of tuberculosis. Thorax 1990;45:403-8.
6. WHO Tuberculosis Programme: Framework for effective tuberculosis control. Geneva: World Health Organization; 1994.WHO/TB/94.
7. Treatment for Tuberculosis. Guidelines for National Programmes. Geneva: World Health Organization; 1998. WHO/TB/97.220.
8. Treatment of tuberculosis. Guidelines for National Programmes. 3 rd ed. Geneva: World Health Organization; 2003. WHO/CD5/TB 2003.313.
9. World Health Organization. Treatment of tuberculosis: Guidelines for national programmes. Geneva: World Health Organization; WHO/CDS/TB/2008.
10. Veen J. Drug resistant tuberculosis: Back to sanatoria, surgery and cod-liver oil? Eur Respir J 1995;8:1073-975.
11. Shimao T. Drug resistance in tuberculosis control. Tubercle 1987;68:5-15. (Pubitemid 17128230)
12. Rastogi N, David HL. Mode of action of antituberculous drugs and mechanisms of resistance in Mycobacterium tuberculosis. Res Microbiol 1993;144:133-43. (Pubitemid 23131006)
13. Vareldzis BP, Grossset J, de Kantor I, Crofton J, Laszlo A, Felten M. Drug-resistant tuberculosis: Laboratory issues. World Health Organization recommendations. Tuber Lung Dis 1994;75:1-7. (Pubitemid 24128754)
14. Lambregts-van Weezenbeek CS, Veen J. Control of drug-resistant tuberculosis. Tuber Lung Dis 1995;76:455-9.
15. Kochi A, Vareldzis B, Styblo K. Multidrug resistant tuberculosis and its control. Res Microbiol 1993;144:104-10. (Pubitemid 23131001)
16. Raviglione M. XDR-TB: Entering the post-antibiotic era? Int J Tuberc Lung Dis 2006;10:1185-7 (Pubitemid 44713471)
17. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-91.
18. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-5.
19. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: The new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007;29:423-7. (Pubitemid 46372084)
20. Velayati AA, Masjedi MR, Farnia, P, Tabarsi P, Ghanavi J, ZiaZarifi A. Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli: Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran. Chest 2009;136:420-5.
21. Schluger NW. Drug-resistant tuberculosis: What is to be done? Chest 2009;136:333-5.
22. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010;16:186-93.
23. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009;7:81-7.
24. Davison DT, Le HL Drug treatment of tuberculosis-1992 Drugs 1992;43:651-73.
25. Vanscoy RE, Wilkowske CJ. Antituberculosis agents. Mayo Clin Proc 1992;67:179-87.
26. Iseman MD, Youngchaiyud P. Update treatment of multi drug resistant tuberculosis, proceedings of a sponsored symposium to the 29 th world conference of the IUATLD/UICTMR. Bangkok, Thailand: Chemotherapy S. Vol. 45, Suppl 2. 1998.
27. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization; 1997. WHO/TB/96.210.
28. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2006. WHO/HTM/TB/2006.361
29. Guidelines for programmatic management of drug resistant tuberculosis. Emergency Update 2008. Geneva: World Health Organization; 2008. WHO/HTM/TB 2008.402.
30. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9.
31. Mitchison DA. Role of individual drug in chemotherapy of tuberculosis. Int J Tuber Lung Dis 2000;4:790-800.
32. Rouillon A. The mutual assistance programme of the IUATLD. Development, contribution and significance. Bull Int Union Tuberc Lung Dis 1991;66:159-72.
33. Espinal MA. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 2003;7:607-8.
34. Quy HT, Lan NT, Borgdorff MW, Grosset J, Linh PD, Tung LB, et al. Drug resistance among failure and relapse cases of tuberculosis: Is the standard retreatment regimen adequate? Int J Tuberc Lung Dis 2003;7:631-6. (Pubitemid 36806857)
35. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008;178:306-12.
36. WHO/CDS/TB/2003.313 Treatment of tuberculosis: Guidelines for national programmes. 3 rd ed. Revision approved by STAG. Geneva: WHO; 2004
37. World Health Organization. Treatment of tuberculosis: Guidelines. 4th ed. Geneva: WHO. 2009. WHO/HTM/TB/2009.420.
38. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: A systematic review and meta-analysis. PLoS Med 2009;6:e1000150.
39. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment - induced hepatotoxicity: Role of predictive factors. Post Grad Med J 1996;71:359-62.
40. Mirchandani LV, Joshi JM. Jaundice due to antituberculosis drugs- a dose related phenomenon. J Assoc Phy India 1995;43:767-9.
41. Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations: API TB consensus guidelines 2006. J Assoc Physicians India 2006;54:219-34.
42. Harries AD, Maher D. TB/HIV: A clinical manual. Geneva: World Health Organization; 1996. WHO/TB/96.200.
43. API TB consensus guidelines 2006: Management of Pulmonary Tuberculosis, Extra-pulmonary Tuberculosis and Tuberculosis in Special Situations. J Assoc Physicians India 2006;54:219-34.
44. Anglaret X, Saba J, Perronne C, Lacassin F, Longuet P, Leport C. Emperic anti-tuberculosis treatment, benefit for early diagnosis and treatment of tuberculosis. Tuber lung Dis 1994;75:334-40. (Pubitemid 24336529)
45. Crofton J. Persistent fever in pulmonary tuberculosis. BMJ 1997;314:1347-8.
46. Gold JA. Fever Curve as an Indicator for Steroid Therapy in Miliary Tuberculosis. Chest 1961;40:171-5.
47. Lenzini L, Rottoli P, Rottoli L. The spectrum of human tuberculosis. Clin Exp Immonol 1977;27:230-7. (Pubitemid 8035689)
48. Breen R, Smith C, Bettinson H, Dart S, Bannister B, Johnson M. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004;59:704-7. (Pubitemid 39061536)
49. Campbell IA. Treatment of superficial tuberculosis lymphadenitis. Tubercle 1990;71:1-3.
50. Humphries M. The management of tuberculosis meningitis. Editorial Thorax 1992;47:577-80.
51. Culuver J. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet 1984;1:1971.
52. Dunath J, Khan FA. Tuberculous and post tuberculous bronchopleural fistula. Chest 1984;80:697-703.
53. Allen MB, Cooka NJ. Corticosteroids and tuberculosis. Br Med J 1991;303:871-2.
54. Treasure RL, Seaworth BJ. Current role of surgery in Mycobacterium tuberculosis. Ann Thorac Surg 1995;59:1405-7.
55. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tub Lung Dis 1995;76:109-13.
56. Siegler DI, Burley DM, Bryant M, Citron KM, Standen SM. Effect of meals on rifampicin absorption. Lancet 1971;2:197-8.
57. Purohit SD, Sarkar SK, Gupta ML, Jain DK, Gupta PR, Mehta YR. Dietary constituents and rifampicin absorption. Tubercle 1987;68:151-2. (Pubitemid 17099441)
58. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999;115:12-8. (Pubitemid 29047048)
59. Rouillon A. Defaulters" and "Motivation." Bull Int Union Tuberc 1972;47:58-63.
60. Nahid P, Pai Mand, Hopewell PC. Advances in the Diagnosis and Treatment of Tuberculosis. Proc Am Thorac Soc 2006;3:103-10.
61. Wright J, Walley J, Philip A, Pushpananthan S, Dlamini E, Newell J, et al. Direct observation of treatment for tuberculosis: A randomized controlled trial of community health workers versus family members. Trop Med Int Health 2004;9:559-65. (Pubitemid 38657280)
62. Gasner MR, Maw KL, Feldman GE, Fujiwara PI, Frieden TR. The use of legal action in New York City to ensure treatment of tuberculosis. New Engl J Med 1999;340:359-66. (Pubitemid 29090802)
63. Coker RJ. From Chaos to Coercion: Detention and the Control of Tuberculosis. London: St Martins Press; 2000. p. 304.
64. New York City Tuberculosis Working Group. Developing a system for tuberculosis prevention and care in New York City. New York: United Hospital Fund; 1992.
65. Dubos RJ, Dubos J. The White Plague-Tuberculosis, Man and Society. Boston: Little, Brown and Company; 1952.
66. Preventing Extremely Drug Resistant Tuberculosis: Directly Observed Treatment Is The Only Answer. Indian J Chest Dis Allied Sci 2008;50:183-5.
67. Wise J. Fast action urged to halt deadly TB. Bull World Health Organ 2007;85:325-420.